The purpose of this study is to evaluate safety and tolerability of BHV3000 (rimegepant).
| Study Type: |
Interventional (Clinical Trial) |
| Estimated Enrollment: |
210 participants |
| Allocation: |
Randomized |
| Intervention Model: |
Parallel Assignment |
| Masking: |
Double (Participant, Care Provider) |
| Primary Purpose: |
Prevention |
| Official Title: |
Melatonin for Adolescent Migraine Prevention Study (The MAP Study). |
| Actual Study Start Date: |
*August 2, 2017 |
| Estimated Primary Completion Date: |
*June 2021 |
| Estimated Study Completion Date: |
*June 2021 |
Contact
| Contact: Amy A Gelfand, MD |
415-885-7832 Amy.Gelfand@ucsf.edu |
| Contact: Laura A Dapkus, NCPT |
415-885-7832 Laura.Dapkus@ucsf.edu |
| ClinicalTrials.gov Identifier: |
NCT03150797 |
For enrollment please visit www.clinicaltrials.gov.
